Sign in

Michael Jain

@michaeldjain.bsky.social
183 followers 55 following 16 posts

Lymphoma and CAR T at Moffitt Cancer Center in Tampa, Florida

PostsRepliesMedia
Reposted by Michael Jain
Thiago Carvalho @cyrilpedia.bsky.social · 24/01/2025
'Why we have evolved so many cytokines for so few transcriptional regulators is not entirely known, but it suggests that the diversity in cell types that can send a signal and cell types that can receive them is more important than diversity in transcriptional programs.'
cell.com
Cytokines in cancer
Kureshi and Dougan discuss the roles of cytokines in the tumor microenvironment. Although there is a sophisticated understanding of cytokine networks, therapeutically targeting cytokine pathways in ca...
03310
Michael Jain @michaeldjain.bsky.social · 21/01/2025
We had visitors @moffittnews.bsky.social today!
050
Michael Jain @michaeldjain.bsky.social · 17/12/2024
Paper in Cell finds that YTHDF2 degrades CD19 and MHC II mRNA while promoting ATP synthesis in B cell malignancies. Could be a mediator of resistance to CD19-targeted therapies.
030
Michael Jain @michaeldjain.bsky.social · 10/12/2024
Two incredibly important abstracts presented by @moffittnews.bsky.social myeloma investigators at #ASH24. 1/3
111
Michael Jain @michaeldjain.bsky.social · 08/12/2024
Lawrence David (Duke) presents “FoodSeq” - everything we eat is alive and has a genome. Some DNA remains undigested. By 16S seq of stool, he can see everything we have eaten, with an alpha diversity “diet diversity” score. Followed diets of transplant patients just by following stool samples! #ASH24
020
Michael Jain @michaeldjain.bsky.social · 08/12/2024
Controversial opinion: in lymphoma, investigators will subcategorize into many clusters and claim a biology for one of the clusters. This is fine, but it is nearly impossible to validate this data or do a clinical trial. If there are 5-10 clusters, we need 5-10x the number of patients.
010
Michael Jain @michaeldjain.bsky.social · 08/12/2024
Trang Vu (Ruella lab/Vittoria bio) shows that KO of CD5 in CAR T cells leads to better function by increasing JAK/STAT signaling. Clinical trial in T cell lymphoma underway. #ASH24
030
Michael Jain @michaeldjain.bsky.social · 08/12/2024
Sleiman (Saar Gill lab UPenn) presents an EGFR-tagged IL-2 that can only bind to their CAR T cells and not non-CAR cells. In a macaque model, saw CRS and B cell aplasia without needing lymphodepleting chemotherapy. “Cis-targeted IL-2”. #ASH24
010
Michael Jain @michaeldjain.bsky.social · 08/12/2024
Josh Brody (Mt Sinai) shows that most lymphoma biopsies have a few CD20 negative cells (some more than others). They have a plasmablastic phenotype and may be targetable. Q - do patients who relapse after bispecifics and are CD20 neg have a more plasmablastic phenotype in their relapsed lymphoma?
000
Michael Jain @michaeldjain.bsky.social · 08/12/2024
David Stahl (Cologne) shows that myeloid cells in the DLBCL TME express CSFR1 and have poor patient outcomes after CAR T. Axatilimab is a GVHD drug that blocks CSFR1 and could improve outcomes. Interestingly, CSF1 ligand may be from Tregs. #ASH24
000
Michael Jain @michaeldjain.bsky.social · 08/12/2024
Kelvin Mo (Stanford) shows that M2 macrophages in the DLBCL TME produce CCL8/CCL13 and have a high IFN signature, associating with poor clinical outcomes after CART. At Moffitt we have a clinical trial of a JAK inhibitor that we think will reduce myeloid IFN in highly inflamed CAR T patients.
010
Michael Jain @michaeldjain.bsky.social · 08/12/2024
Fascinating work by Bacchisio Ziccheddu and Francesco Maura (UMiami) outlining that tumor loss of MHC I (with resultant NK inhibition) associates with relapse after CAR T in patients treated by us at Moffitt. Suggests that CAR T needs to recruit other aspects of immunity to work!
010
Michael Jain @michaeldjain.bsky.social · 06/12/2024
Fascinating study where they label CAR T cells and follow their trafficking in patients! Immediate biodistribution is to the liver and spleen, and they can see whether the Car goes into extramedullary masses. What explains differences between patients?
164
Michael Jain @michaeldjain.bsky.social · 23/11/2024
One person’s immunodeficiency could be another person’s lymphoma target
000